Related Experiment Video
Updated: Feb 16, 2026

In Vitro Differentiation of Mouse Granulocyte-macrophage-colony-stimulating Factor GM-CSF-producing T Helper THGM Cells
Published on: September 10, 2018
Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated
Nipun Verma1, Amritjyot Kaur2, Ratiram Sharma3
1Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Insights
Granulocyte-colony stimulating factor (G-CSF) improved survival and disease severity in decompensated cirrhosis patients. Growth hormone (GH) did not offer additional benefits, but G-CSF therapy was well tolerated.
Area of Science:
- Hepatology
- Stem Cell Mobilization
- Clinical Trials
Background:
- Decompensated cirrhosis (DC) has high mortality, with liver transplantation (LT) limited by donor organ availability.
- High waitlist mortality underscores the need for effective therapies to improve outcomes for DC patients awaiting LT.
- Investigating novel therapeutic approaches is crucial for managing DC and reducing mortality.
Purpose of the Study:
- To evaluate the impact of granulocyte-colony stimulating factor (G-CSF) with or without growth hormone (GH) on transplant-free survival (TFS) in DC patients.
- To assess secondary outcomes including hematopoietic stem cell mobilization, clinical scores, liver stiffness, nutrition, infection episodes, and quality of life (QOL).
- To determine if GH provides additional benefits when combined with G-CSF therapy in DC patients.
Main Methods:
- A randomized controlled trial involving 65 DC patients assigned to standard medical therapy (SMT) plus G-CSF/GH, SMT plus G-CSF, or SMT alone.
- Primary outcome measured was 12-month TFS.
- Secondary outcomes included CD34+ cell mobilization, clinical scores, liver stiffness, nutritional status, infection rates, and QOL at 12 months.
Main Results:
- Both G-CSF with or without GH significantly improved 12-month TFS compared to SMT alone (P = 0.001).
- G-CSF therapy led to increased CD34+ cell mobilization at day 6 (P < 0.001).
- Significant improvements were observed in clinical scores, nutrition, ascites control, liver stiffness, infection episodes, and QOL in G-CSF treated groups at 12 months (P < 0.05).
Conclusions:
- Multiple courses of G-CSF effectively improved TFS, mobilized stem cells, and enhanced various clinical parameters in DC patients.
- G-CSF therapy also reduced infections and the need for LT, demonstrating its therapeutic potential.
- Growth hormone (GH) did not confer additional benefits when used alongside G-CSF in this patient population.
Abstract:
Decompensated cirrhosis (DC) carries a high mortality. Liver transplantation (LT) is the treatment of choice; however, the limited availability of donor organs has resulted in high waitlist mortality. The present study investigated the impact of multiple courses of granulocyte-colony stimulating factor (G-CSF) with or without growth hormone (GH) in these patients. Sixty-five patients with DC were randomized to standard medical therapy (SMT) plus G-CSF 3 monthly plus GH daily (group A; n = 23) or SMT plus G-CSF (group B; n = 21) or SMT alone (group C; n = 21). The primary outcome was transplant-free survival (TFS) at 12 months. Secondary outcomes were mobilization of CD34+ cells at day 6 and improvement in clinical scores, liver stiffness, nutrition, episodes of infection, and quality of life (QOL) at 12 months. There was significantly better 12-month TFS in groups A and B than in group C (P = 0.001). At day 6 of therapy, CD34+ cells increased in groups A and B compared to baseline (P < 0.001). There was a significant decrease in clinical scores, improvement in nutrition, better control of ascites, reduction in liver stiffness, lesser infection episodes, and improvement in QOL scores in groups A and B at 12 months as compared to baseline (P < 0.05). The therapies were well tolerated.
Conclusion:
Multiple courses of G-CSF improved 12-month TFS, mobilized hematopoietic stem cells, improved disease severity scores, nutrition, fibrosis, QOL scores, ascites control, reduced infections, and the need for LT in patients with DC. However, the use of GH was not found to have any additional benefit. (Hepatology 2017).
More Related Videos
08:53Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
12:02Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells
Published on: November 11, 2021
Related Concept Videos
Types of Hormones
Hormonal Regulation
Hormonal Regulation
Plant Hormones
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH